Logotype for Max Healthcare Institute Limited

Max Healthcare Institute (543220) Q2 26/27 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Max Healthcare Institute Limited

Q2 26/27 earnings summary

3 Nov, 2026

Executive summary

  • Q2 FY27 network gross revenue rose 20% YoY to INR 3,219 crore; operating EBITDA grew 18% to INR 820 crore and normalized PAT rose 10% to INR 448 crore.

  • Occupancy was 77% despite 14% YoY growth in operational beds; occupied bed days increased 13% YoY.

  • H1 FY27 network gross revenue grew 18% to INR 6,200 crore and operating EBITDA rose 17% to INR 1,524 crore; normalized PAT increased 7% to INR 805 crore.

  • Excluding oncology, gross revenue grew 25% in Q2 and 23% in H1; Smart beds reached EBITDA breakeven within three months.

Financial highlights

  • Q2 network gross revenue was INR 3,219 crore, up 20% YoY and 8% QoQ; net revenue was INR 3,055 crore, up 18% YoY.

  • Q2 operating EBITDA was INR 820 crore, up 18% YoY; reported EBITDA was INR 797 crore.

  • Q2 PAT was INR 448 crore, up 10% on a normalized basis after adjusting the prior-year quarter for a one-time INR 149 crore tax gain; consolidated reported net profit was INR 414.45 crore versus INR 491.30 crore.

  • H1 net revenue was INR 5,890 crore, up 17%, and reported EBITDA was INR 1,480 crore; normalized PAT was INR 805 crore versus INR 750 crore.

  • Q2 ARPP was INR 2.31 lakh, up 8% YoY; excluding oncology, ARPP increased 11%.

Outlook and guidance

  • Remaining 140 beds at Max Smart, Saket, are expected to open after Diwali Puja; 100 beds at Max Lucknow are planned over the next two quarters.

  • Noida and Vaishali redevelopment projects add 85 and 60 beds, respectively; commissioning is planned within 15 and 24 months.

  • The 525-bed Gurugram hospital is scheduled for completion in April 2027 at a revised project cost of ~INR 1,143 crore; phased commissioning is expected to begin with 150–200 beds.

  • Zirakpur is scheduled for commissioning by December 2027, with an estimated initial EBITDA loss of INR 30 crore; Gurugram peak EBITDA loss is estimated at INR 40–50 crore.

  • Q3/Q4 revenue growth is expected to benefit as prior-year chemotherapy-drug impacts annualize and new capacity contributes; Bhubaneswar renovation is expected to run for ~12 months.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Max Healthcare Institute